News on qPCR, digital PCR, amplification, point-of-care testing platforms in genetics, genomics, and molecular diagnostics.
The test has been authorized for use with individual respiratory specimens, as well as with pooled specimens containing up to five samples.
Invitae is working with Bristol Myers Squibb, Janssen, Novartis, and Genentech to advance an NGS panel to gauge the efficacy of AML treatments in trials.
The firm plans to begin its OTC efforts with a COVID antigen test but also sees potential in migrating other infectious disease tests.
The funding will be used to validate the Simplexa COVID-19 Direct kit and Simplexa COVID-19 & Flu A/B Direct kit and to submit them to the FDA for 510(k) clearance.
The firm is projecting COVID-19 testing revenues of $865 million in the recently completed quarter, including $685 million in Veritor immunoassay sales.
